Trade Ocugen, Inc. - OCGN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.0008 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Ocugen Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 0.388 |
| Open* | 0.39 |
| 1-Year Change* | -70.9% |
| Day's Range* | 0.3862 - 0.3919 |
| 52 wk Range | 0.35-1.62 |
| Average Volume (10 days) | 1.21M |
| Average Volume (3 months) | 36.09M |
| Market Cap | 99.27M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 256.50M |
| Revenue | N/A |
| EPS | -0.32 |
| Dividend (Yield %) | N/A |
| Beta | 3.97 |
| Next Earnings Date | Feb 26, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 8, 2023 | 0.3883 | -0.0017 | -0.44% | 0.3900 | 0.3942 | 0.3862 |
| Dec 7, 2023 | 0.3880 | -0.0078 | -1.97% | 0.3958 | 0.3961 | 0.3849 |
| Dec 6, 2023 | 0.3950 | 0.0051 | 1.31% | 0.3899 | 0.3981 | 0.3860 |
| Dec 5, 2023 | 0.3891 | -0.0010 | -0.26% | 0.3901 | 0.3962 | 0.3859 |
| Dec 4, 2023 | 0.3940 | 0.0051 | 1.31% | 0.3889 | 0.3960 | 0.3859 |
| Dec 1, 2023 | 0.3914 | 0.0160 | 4.26% | 0.3754 | 0.3924 | 0.3749 |
| Nov 30, 2023 | 0.3809 | 0.0010 | 0.26% | 0.3799 | 0.3849 | 0.3739 |
| Nov 29, 2023 | 0.3813 | 0.0014 | 0.37% | 0.3799 | 0.3929 | 0.3798 |
| Nov 28, 2023 | 0.3780 | -0.0117 | -3.00% | 0.3897 | 0.3897 | 0.3708 |
| Nov 27, 2023 | 0.3913 | -0.0006 | -0.15% | 0.3919 | 0.4044 | 0.3835 |
| Nov 24, 2023 | 0.3949 | 0.0140 | 3.68% | 0.3809 | 0.3969 | 0.3799 |
| Nov 22, 2023 | 0.3799 | -0.0011 | -0.29% | 0.3810 | 0.3849 | 0.3719 |
| Nov 21, 2023 | 0.3829 | -0.0098 | -2.50% | 0.3927 | 0.3995 | 0.3806 |
| Nov 20, 2023 | 0.4046 | 0.0247 | 6.50% | 0.3799 | 0.4085 | 0.3779 |
| Nov 17, 2023 | 0.3860 | 0.0028 | 0.73% | 0.3832 | 0.3883 | 0.3659 |
| Nov 16, 2023 | 0.3608 | -0.0141 | -3.76% | 0.3749 | 0.3769 | 0.3608 |
| Nov 15, 2023 | 0.3775 | 0.0076 | 2.05% | 0.3699 | 0.3878 | 0.3699 |
| Nov 14, 2023 | 0.3699 | 0.0100 | 2.78% | 0.3599 | 0.3729 | 0.3524 |
| Nov 13, 2023 | 0.3573 | -0.0027 | -0.75% | 0.3600 | 0.3609 | 0.3508 |
| Nov 10, 2023 | 0.3599 | 0.0000 | 0.00% | 0.3599 | 0.3699 | 0.3513 |
Ocugen, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, February 26, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Q4 2023 Ocugen Inc Earnings Release Q4 2023 Ocugen Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0.04262 | 0 | 0 |
| Revenue | 0 | 0.04262 | 0 | ||
| Total Operating Expense | 84.868 | 57.628 | 21.3273 | 14.5038 | 28.568 |
| Selling/General/Admin. Expenses, Total | 35.111 | 22.92 | 7.97405 | 6.0771 | 10.204 |
| Research & Development | 49.757 | 35.108 | 13.3533 | 8.08552 | 15.634 |
| Unusual Expense (Income) | -0.4 | 0 | 0.34114 | 2.73 | |
| Operating Income | -84.868 | -57.628 | -21.2847 | -14.5038 | -28.568 |
| Interest Income (Expense), Net Non-Operating | -0.079 | -0.71989 | -4.95401 | 20.031 | |
| Other, Net | 3.517 | -0.71 | 0.18266 | -0.78487 | -0.106 |
| Net Income Before Taxes | -81.351 | -58.417 | -21.822 | -20.2426 | -8.643 |
| Net Income After Taxes | -81.351 | -58.365 | -21.822 | -20.2426 | -8.643 |
| Net Income Before Extra. Items | -81.351 | -58.365 | -21.822 | -20.2426 | -8.643 |
| Net Income | -81.351 | -58.365 | -21.822 | -20.2426 | -8.643 |
| Total Adjustments to Net Income | 0 | -12.5463 | 0.121 | ||
| Income Available to Common Excl. Extra. Items | -81.351 | -58.365 | -34.3683 | -20.2426 | -8.522 |
| Income Available to Common Incl. Extra. Items | -81.351 | -58.365 | -34.3683 | -20.2426 | -8.522 |
| Diluted Net Income | -81.351 | -58.365 | -34.3683 | -20.2426 | -8.522 |
| Diluted Weighted Average Shares | 214.6 | 195.013 | 112.236 | 13.8938 | 0.60676 |
| Diluted EPS Excluding Extraordinary Items | -0.37908 | -0.29929 | -0.30621 | -1.45695 | -14.045 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -0.37908 | -0.30062 | -0.30621 | -1.4324 | -9.54575 |
| Total Extraordinary Items | 0 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 23.733 | 17.751 | 24.15 | 23.119 | 19.565 |
| Selling/General/Admin. Expenses, Total | 9.564 | 8.193 | 6.937 | 7.497 | 10.558 |
| Research & Development | 14.169 | 9.558 | 17.213 | 15.622 | 9.007 |
| Operating Income | -23.733 | -17.751 | -24.15 | -23.119 | -19.565 |
| Interest Income (Expense), Net Non-Operating | |||||
| Net Income Before Taxes | -22.925 | -16.498 | -21.939 | -21.922 | -19.471 |
| Net Income After Taxes | -22.925 | -16.498 | -21.939 | -21.922 | -19.471 |
| Net Income Before Extra. Items | -22.925 | -16.498 | -21.939 | -21.922 | -19.471 |
| Net Income | -22.925 | -16.498 | -21.939 | -21.922 | -19.471 |
| Income Available to Common Excl. Extra. Items | -22.925 | -16.499 | -21.939 | -21.922 | -19.471 |
| Income Available to Common Incl. Extra. Items | -22.925 | -16.499 | -21.939 | -21.922 | -19.471 |
| Diluted Net Income | -22.925 | -16.499 | -21.939 | -21.922 | -19.471 |
| Diluted Weighted Average Shares | 238.311 | 225.524 | 220.133 | 216.591 | 215.863 |
| Diluted EPS Excluding Extraordinary Items | -0.0962 | -0.07316 | -0.09966 | -0.10121 | -0.0902 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.0962 | -0.07316 | -0.09966 | -0.10121 | -0.0902 |
| Revenue | |||||
| Other, Net | 0.808 | 1.253 | 2.211 | 1.197 | 0.094 |
| Total Adjustments to Net Income | -0.001 | ||||
| Unusual Expense (Income) |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 98.492 | 102.646 | 25.8777 | 15.7662 | 16.4 |
| Cash and Short Term Investments | 90.934 | 94.958 | 24.0393 | 7.44405 | 15.542 |
| Cash & Equivalents | 77.563 | 94.958 | 24.0393 | 7.44405 | 15.542 |
| Prepaid Expenses | 7.558 | 2.7 | 1.83836 | 1.32217 | 0.686 |
| Total Assets | 108.632 | 105.761 | 27.3764 | 16.8074 | 17.428 |
| Property/Plant/Equipment, Total - Net | 9.963 | 2.751 | 1.06662 | 0.22246 | 0.141 |
| Intangibles, Net | |||||
| Other Long Term Assets, Total | 0.177 | 0.364 | 0.43205 | 0.81876 | 0.887 |
| Total Current Liabilities | 18.46 | 7 | 3.61355 | 4.54396 | 2.873 |
| Accounts Payable | 8.062 | 2.312 | 0.39503 | 1.89561 | 1.59 |
| Accrued Expenses | 10.398 | 4.688 | 2.97464 | 2.44236 | 1 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.23412 | 0 | 0 | |
| Other Current Liabilities, Total | 0.00976 | 0.20599 | 0.283 | ||
| Total Liabilities | 24.58 | 9.943 | 5.82591 | 5.78904 | 17.886 |
| Total Long Term Debt | 2.289 | 1.712 | 1.82304 | 1.07212 | 0 |
| Long Term Debt | 2.289 | 1.712 | 1.82304 | 1.07212 | |
| Other Liabilities, Total | 3.831 | 1.231 | 0.38932 | 0.17295 | 15.013 |
| Total Equity | 84.052 | 95.818 | 21.5504 | 11.0184 | -0.458 |
| Common Stock | 2.217 | 1.995 | 1.84133 | 0.52747 | 0.513 |
| Additional Paid-In Capital | 294.874 | 225.537 | 93.0587 | 62.0186 | 215.859 |
| Retained Earnings (Accumulated Deficit) | -213.018 | -131.667 | -73.3018 | -51.4798 | -216.83 |
| Total Liabilities & Shareholders’ Equity | 108.632 | 105.761 | 27.3764 | 16.8074 | 17.428 |
| Total Common Shares Outstanding | 221.6 | 199.381 | 184.012 | 52.6252 | 1.03376 |
| Short Term Investments | 13.371 | 0 | |||
| Redeemable Preferred Stock | 0.001 | 0.001 | 0 | 0 | |
| Other Equity, Total | 0.026 | 0 | |||
| Other Current Assets, Total | 4.988 | 0 | 7 | 0.172 | |
| Property/Plant/Equipment, Total - Gross | 10.584 | 3.125 | 1.29231 | 10.427 | |
| Accumulated Depreciation, Total | -0.621 | -0.374 | -0.2257 | -10.286 | |
| Treasury Stock - Common | -0.048 | -0.048 | -0.04786 | -0.04786 | |
| Total Preferred Shares Outstanding | 0.05475 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 56.558 | 73.452 | 84.401 | 98.492 | 107.497 |
| Cash and Short Term Investments | 53.477 | 70.578 | 76.721 | 90.934 | 101.602 |
| Cash & Equivalents | 53.477 | 70.578 | 68.259 | 77.563 | 101.602 |
| Prepaid Expenses | 3.081 | 2.874 | 7.68 | 7.558 | 5.895 |
| Other Current Assets, Total | |||||
| Total Assets | 74.687 | 88.976 | 96.299 | 108.632 | 116.239 |
| Property/Plant/Equipment, Total - Net | 14.469 | 11.72 | 7.952 | 9.963 | 8.557 |
| Property/Plant/Equipment, Total - Gross | 15.528 | 12.613 | 8.739 | 10.584 | 9.135 |
| Accumulated Depreciation, Total | -1.059 | -0.893 | -0.787 | -0.621 | -0.578 |
| Other Long Term Assets, Total | 3.66 | 3.804 | 3.946 | 0.177 | 0.185 |
| Total Current Liabilities | 11.136 | 13.46 | 15.683 | 18.46 | 14.907 |
| Accounts Payable | 2.921 | 3.881 | 8.092 | 8.062 | 6.46 |
| Accrued Expenses | 6.939 | 8.313 | 6.335 | 10.398 | 8.447 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 1.276 | 1.266 | 1.256 | ||
| Total Liabilities | 16.292 | 18.695 | 20.499 | 24.58 | 20.936 |
| Total Long Term Debt | 1.495 | 1.472 | 1.058 | 2.289 | 2.265 |
| Long Term Debt | 1.495 | 1.472 | 1.058 | 2.289 | 2.265 |
| Other Liabilities, Total | 3.661 | 3.763 | 3.758 | 3.831 | 3.764 |
| Total Equity | 58.395 | 70.281 | 75.8 | 84.052 | 95.303 |
| Common Stock | 2.566 | 2.566 | 2.265 | 2.217 | 2.168 |
| Additional Paid-In Capital | 322.452 | 320.181 | 303.073 | 294.874 | 284.231 |
| Retained Earnings (Accumulated Deficit) | -266.603 | -252.441 | -229.516 | -213.018 | -191.079 |
| Treasury Stock - Common | -0.048 | -0.048 | -0.048 | -0.048 | -0.048 |
| Other Equity, Total | 0.027 | 0.022 | 0.025 | 0.026 | 0.03 |
| Total Liabilities & Shareholders’ Equity | 74.687 | 88.976 | 96.299 | 108.632 | 116.239 |
| Total Common Shares Outstanding | 256.5 | 256.487 | 226.427 | 221.6 | 216.688 |
| Redeemable Preferred Stock | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
| Short Term Investments | 0 | 0 | 8.462 | 13.371 | |
| Total Preferred Shares Outstanding | 0.05475 | 0.05475 | 0.05475 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -81.351 | -58.365 | -21.822 | -20.2426 | -8.643 |
| Cash From Operating Activities | -60.079 | -47.941 | -14.7087 | -16.8933 | -15.777 |
| Cash From Operating Activities | 0.48 | 0.229 | 0.10211 | 0.06061 | 0.45 |
| Non-Cash Items | 11.597 | 7.757 | 8.2213 | 6.40129 | -14.779 |
| Cash Taxes Paid | 0 | 0.052 | 0.105 | ||
| Cash Interest Paid | 0.001 | ||||
| Changes in Working Capital | 9.195 | 2.438 | -1.21018 | -3.11255 | 7.195 |
| Cash From Investing Activities | -16.967 | -1.816 | -0.30683 | -2.35672 | -1.113 |
| Capital Expenditures | -4.457 | -1.066 | -0.30683 | -0.02945 | -2.013 |
| Cash From Financing Activities | 59.475 | 120.676 | 31.611 | 25.0665 | 25.351 |
| Financing Cash Flow Items | -0.592 | -8.525 | -1.48355 | -0.17293 | -0.178 |
| Issuance (Retirement) of Stock, Net | 59.567 | 129.211 | 37.822 | 23.7294 | 25.529 |
| Net Change in Cash | -17.546 | 70.919 | 16.5955 | 5.81646 | 8.461 |
| Other Investing Cash Flow Items, Total | -12.51 | -0.75 | 0 | -2.32727 | 0.9 |
| Issuance (Retirement) of Debt, Net | 0.5 | -0.01 | -4.72744 | 1.51 | |
| Foreign Exchange Effects | 0.025 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -16.498 | -81.351 | -59.412 | -37.49 | -18.019 |
| Cash From Operating Activities | -18.24 | -60.079 | -43.165 | -28.863 | -15.066 |
| Cash From Operating Activities | 0.174 | 0.48 | 0.307 | 0.166 | 0.076 |
| Non-Cash Items | 3.053 | 11.597 | 7.721 | 5.75 | 3.497 |
| Changes in Working Capital | -4.969 | 9.195 | 8.219 | 2.711 | -0.62 |
| Cash From Investing Activities | 3.441 | -16.967 | -1.672 | -1.589 | -0.223 |
| Capital Expenditures | -1.612 | -4.457 | -2.433 | -1.589 | -0.223 |
| Cash From Financing Activities | 5.496 | 59.475 | 51.3 | 50.338 | 50.102 |
| Financing Cash Flow Items | -0.235 | -0.592 | -0.398 | -0.248 | -0.075 |
| Issuance (Retirement) of Stock, Net | 5.731 | 59.567 | 51.198 | 50.586 | 50.177 |
| Issuance (Retirement) of Debt, Net | 0.5 | 0.5 | 0 | 0 | |
| Net Change in Cash | -9.304 | -17.546 | 6.493 | 19.896 | 34.813 |
| Other Investing Cash Flow Items, Total | 5.053 | -12.51 | 0.761 | 0 | |
| Cash Taxes Paid | 0 | 0 | |||
| Foreign Exchange Effects | -0.001 | 0.025 | 0.03 | 0.01 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.6031 | 11806345 | -1208505 | 2023-06-30 | LOW |
| Luminus Management, L.L.C. | Hedge Fund | 1.5904 | 4079238 | 4079238 | 2023-06-30 | MED |
| GMT Capital Corp. | Hedge Fund | 1.5292 | 3922198 | 3922198 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.5146 | 3884853 | -10098331 | 2023-06-30 | LOW |
| Millennium Management LLC | Hedge Fund | 1.1761 | 3016537 | 1748855 | 2023-06-30 | HIGH |
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 1.1354 | 2912274 | -62660 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.1162 | 2862968 | -1798365 | 2023-06-30 | LOW |
| Alyeska Investment Group, L.P. | Hedge Fund | 0.9747 | 2500000 | 2500000 | 2023-06-30 | HIGH |
| Renaissance Technologies LLC | Hedge Fund | 0.9635 | 2471156 | 189608 | 2023-06-30 | HIGH |
| KVM Holdings, L.L.C. | Corporation | 0.4465 | 1145299 | 0 | 2023-04-13 | |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 0.4421 | 1134020 | -384808 | 2023-06-30 | LOW |
| D. E. Shaw & Co., L.P. | Hedge Fund | 0.4259 | 1092269 | 1092269 | 2023-06-30 | MED |
| Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 0.4215 | 1081149 | 1081149 | 2023-06-30 | MED |
| Susquehanna International Group, LLP | Investment Advisor | 0.4082 | 1047001 | -1373928 | 2023-06-30 | MED |
| Zhang (Junge) | Individual Investor | 0.3762 | 964904 | 0 | 2023-04-13 | |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3437 | 881626 | -5189880 | 2023-06-30 | LOW |
| Kompella (Uday B.) | Individual Investor | 0.2749 | 705090 | 0 | 2023-04-13 | |
| Citadel Advisors LLC | Hedge Fund | 0.2235 | 573323 | 279457 | 2023-06-30 | LOW |
| Musunuri (Shankar Ph.D) | Individual Investor | 0.1886 | 483636 | -1359897 | 2023-04-13 | HIGH |
| Jane Street Capital, L.L.C. | Research Firm | 0.1819 | 466625 | 33988 | 2023-06-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ocugen, Inc. Company profile
Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine.
Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.
Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.
The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).
The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD).
Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.
Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.
Ocugen is headquartered in Malvern, Pennsylvania.
| Industry: | Biotechnology & Medical Research (NEC) |
11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com